RNS Number : 0377M Renalytix PLC 16 September 2021 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this
RNS Number : 8680L Renalytix PLC 15 September 2021 Second Price Monitoring Extension A second and final Price Monitoring Extension has been activated in this security. The auction call period is extended in this security for a further 5 minutes. Following the first price monitoring extension this
RNS Number : 8670L Renalytix PLC 15 September 2021 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders
RNS Number : 7773L Renalytix PLC 14 September 2021 This announcement contains inside information Renalytix plc (" Renalytix " or the " Company ") Update on MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics NEW YORK , September 14, 2021 - Renalytix
Targeted testing run rate of 300 diabetic kidney disease patients per week in calendar Q4 2021 NEW YORK and SALT LAKE CITY, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) and the Mount Sinai Health System today announced scaled-up implementation of the KidneyIntelX™
RNS Number : 6348L Renalytix PLC 14 September 2021 This announcement contains inside information Renalytix plc (" Renalytix " or the " Company ") Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX TM Enabled Health Care Model Targeted testing run rate of 300 diabetic
RNS Number : 6078L Renalytix PLC 13 September 2021 Renalytix plc (" Renalytix " or the " Company ") Issue of shares under the 2020 employee share purchase plan and Total Voting Rights NEW YORK and SALT LAKE CITY , September 13 2021 - Renalytix Plc (NASDAQ: RNLX) (LSE: RENX)
RNS Number : 8886K Renalytix PLC 06 September 2021 Renalytix plc (" Renalytix " or the " Company ") Director/PDMR Dealing New York , 6 September 2021 - Renalytix (LSE: RENX) announces that it has been advised of the sale by O. James Sterling , the Company's Chief Financial Officer, of 3,000
NEW YORK and SALT LAKE CITY, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today announced the company will be presenting at the upcoming 2021 Wells Fargo Virtual Healthcare Conference. Renalytix’s management is scheduled to participate
RNS Number : 6161K Renalytix PLC 03 September 2021 Renalytix plc (" Renalytix " or the " Company ") Renalytix to present at the 2021 Wells Fargo Virtual Healthcare Conference NEW YORK and SALT LAKE CITY , September 3, 2021 -- Renalytix plc (LSE: RENX) (NASDAQ: RNLX) announces that the
